Markets back down as virus fears take hold again
Published 20-NOV-2020 09:56 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The FTSE 100 dropped 60 points yesterday, mirroring losses in Europe as indices continued to fall from recent highs.
According to Chris Beauchamp, Chief Market Analyst at IG, virus fears have taken hold.
“Virus fears hit an overextended global stock market, knocking European equities sharply lower and pointing towards a weaker start in the US.”
This view was mirrored by eToro analyst Adam Vettese who said, “A worrying rise in Covid cases sees jittery investors sell off stocks. Hot off the heels of the positive news that Pfizer’s vaccine was up to 95% efficacy, the US death count hitting the milestone 250,000 mark caused markets to slide. This shows how delicately poised markets are and that news of a vaccine is not sufficient, approval and vaccinations being rolled out is what will make the real difference.”
We know the markets surged in the last two weeks and Beauchamp says, after these gains “equities now look much more richly-valued, and thus vulnerable to an outbreak of bad news.
“This is precisely what we got in the form of spreading infections in the US but also in Japan, a worrying sign indeed for a country that had been successful earlier in the year in controlling the spread.
“There appears to be little desire to chase equities at these levels, and perhaps rightly so, with markets looking priced for perfection and still vulnerable to some short-term turbulence.
“Speaking of things looking priced for continued good news, Kingfisher has fallen 4% after reporting a strong set of sales figures for Q3. The news appears to more than justify the huge gains in the shares since March, up 120% versus a mere 22% for the index.
“But while the overall investment case remains strong, investors appear content for now to sit and await a better chance to buy back in later in the year.”
The Australian SPI 200 futures contract was down 14 points, or 0.2 per cent, to 6,552 points at 8.30am AEST on Friday.
Tickers
Dow: +0.15%
S&P 500: +0.39%
NASDAQ: +0.87%
FTSE 100: -0.80%
DAX: -0.88%
CAC 40: -0.67%
Asia Dow: -0.74%
Nikkei 225: -0.36%
Hang Seng: -0.71%
ASX 200: +0.25%
AUD: 0.72
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.